Adalimumab for pediatric sympathetic ophthalmia

JAMA Ophthalmol. 2014 Aug;132(8):1022-4. doi: 10.1001/jamaophthalmol.2014.426.

Authors

Joon-Bom Kim¹, Abdallah Jeroudi¹, Sheila T Angeles-Han², Hans E Grossniklaus¹, Steven Yeh¹

Affiliations

¹ Emory Eye Center, Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia.
² Emory Eye Center, Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia2Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia3Children's Hospital of Atlanta, Atlanta, Georgia.

No abstract available

Publication types

Case Reports
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adalimumab
Antibodies, Monoclonal, Humanized / therapeutic use*
Female
Humans
Ophthalmia, Sympathetic / drug therapy*
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Antibodies, Monoclonal, Humanized
Tumor Necrosis Factor-alpha
Adalimumab

Grants and funding